Rilotumumab
Rilotumumab
Rilotumumab (pronounced ril-oh-TOO-moo-mab) is an experimental monoclonal antibody designed for the treatment of cancer. It is developed by Amgen, a multinational biopharmaceutical company.
Etymology
The name "Rilotumumab" follows the INN naming convention for monoclonal antibodies, with the suffix "-mab" indicating it is a monoclonal antibody. The prefix "Rilo-" does not have a specific meaning, as it is part of the stem used to differentiate this specific antibody.
Mechanism of Action
Rilotumumab works by targeting the hepatocyte growth factor (HGF), a protein that can promote the growth of cancer cells. By binding to HGF, Rilotumumab can block its interaction with the c-Met receptor on the surface of cancer cells, thereby inhibiting cell growth and proliferation.
Clinical Trials
Rilotumumab has been tested in several clinical trials for various types of cancer, including gastric cancer and lung cancer. However, in 2014, a phase III trial for gastric cancer was halted due to an increase in the number of deaths in the group receiving Rilotumumab.
Related Terms
External links
- Medical encyclopedia article on Rilotumumab
- Wikipedia's article - Rilotumumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski